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molecule, of porcine origin. It is known to possess various biological effects including antimicrobial properties,
angiogenic and anti-inflammatory activities. Apart from its reported activity as a proteasome inhibitor, a more
comprehensive understanding of its function, at the molecular level, is still lacking. In this study, we used a
label-free shotgun strategy to evaluate the proteomic alterations caused by exposure of cultured fibroblasts to
the peptide PR-11. This approach revealed thatmore than half of the identifiedmolecules were related to signal-
ling, transcription and translation. Proteins directly associated to regulation of angiogenesis and interaction with
the hypoxia-inducible factor 1-α (HIF-1α) were significantly altered. In addition, at least three differentially
expressed molecules of the NF-κB pathway were detected, suggesting an anti-inflammatory property of PR-11.
At last, we demonstrated novel potential ligands of PR-11, through its immobilization for affinity chromatogra-
phy. Among the elutedmolecules, gC1qR, a known complement receptor, appearedmarkedly enriched. This pro-
vided preliminary evidence of a PR-11 ligand possibly involved in the internalization of this peptide. Altogether,
our findings contributed to a better understanding of the cellular pathways affected by PR-39 derivedmolecules.





PR-11 binding proteins1. Introduction
The peptide PR-11, a ~1.4 kDa molecule highly rich in proline and
arginine residues, corresponds to the N-terminal active region of PR-
39, the latter formerly isolated from the small intestine [1] and bone
marrow of pigs [2]. PR-39 acts against a wide spectrum of bacteria,
including clinical isolates resistant to multiple drugs [3,4]. At micromo-
lar concentrations, the peptide is rapidly internalized and interferes
with various cellular processes such as inhibition of DNA synthesis
and translation. At higher levels, a bactericide activity is also observed,
possibly by perturbation of cell membrane stability [5,6]. Aside from
its antimicrobial properties, PR-39 stimulates neutrophil migration [7],
inhibits apoptosis [8–10] and reduces motility and cell proliferation in
cancer tissues [11,12].e Andrade).PR-39 has been shown to bind intracellular SH3 domain-containing
proteins [13] and its role as a proteasome regulator also reported. The
hypoxia signalling and NF-κB pathways are known to be compromised
by PR-39 proteasome-dependent inhibition resulting in angiogenic [14]
and anti-inflammatory effects [15,16], respectively. Sequential C-
terminal residue deletions of PR-39 in parallel to evaluation of the
resulting activity over the 20S proteasome, revealed the requirement
of at least 11 N-terminal amino acids to sustain its inhibitory property,
in a dose-dependent manner [17]. Atomic force microscopy also dem-
onstrated that upon binding of PR-39 and PR-11 to 26S and 20S
proteasomes, their cylindrical architecture is reversibly altered [17].
Given the wide repertoire of biological activities of PR-39 and PR-11
and the limited knowledge of their interfering molecular pathways, we
used a label-free shotgun approach to evaluate the proteome alterations
caused by exposure of cultured fibroblasts to 1 μM PR-11. Our findings
demonstrated that N50% of the identified differentially expressed
proteins are related to cell signalling, transcription and translation. In
addition, using immobilized PR-11 affinity chromatography, we were
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ing of its mechanism of action.2. Materials and methods
2.1. Ethics statement
The procedures involving animals were carried out in accordance
with the Brazilian legislation (11790/2008). They were reviewed and
approved by the local ethics committee on animal experimentation
(CEUA), Universidade Federal de Ouro Preto (UFOP), and received the
protocol number 2013/09.2.2. Synthesis of the PR-11 peptide
PR-11 peptide was chemically synthesized based on the amino acid
composition of the 11 N-terminal residues (RRRPRPPYLPR) of PR-39.
PR-11 was purified by HPLC using reversed-phase chromatography
(Shimadzu Scientific Instruments) (Supplementary Fig. 1), identified
by direct injection in an IT-TOFmass spectrometer (Shimadzu Scientific
Instruments) and finally reconstituted in water. Peptide concentration
was calculated using the molar extinction coefficient at 280 nm of its
constituent tyrosine residue (1280 M−1 cm−1).2.3. Fibroblasts culture and exposure to PR-11 peptide
Fibroblasts were obtained from lungs of neonate Wistar rats, aged
2 days and of approximately 5 g weight. Briefly, after removal of the
lungs, these were washed in 1× ADS buffer (115 mM NaCl; 20 mM
Hepes, 1 mM Na2HPO4, 5 mM D-glucose; 5 mM KCl; 1.6 mM MgSO4)
and subjected to 3 cycles of digestion with 0.8 mg/mL pancreatin
(Sigma-Aldrich) for 20min at 37 °C. Cells were recovered by centrifuga-
tion at 1.000 ×g for 10min and resuspended in DMEMmedium supple-
mented with 15% v/v fetal bovine serum and 1% v/v penicillin/
streptomycin. Prior to exposure of cells to PR-11, a minimum cell con-
fluence of N90% throughout the well was required under microscopic
observation and the supernatant should contain a negligible number
of detached cells. Primary fibroblast cultures (unique passage) were
exposed to 1 μM PR-11 during 2, 6 and 10 h. Control cultures, in
which water was added instead of the water-soluble peptide, were
obtained for the same time points. At the end of the incubation periods,
the supernatant containing PR-11 peptidewas completely removed and
the cells were gently detached from the wells using the TrypLE reagent
(Gibco). These were finally recovered by centrifugation. The experi-
ments were performed in biological triplicates.2.4. Soluble protein extract and in solution digestion
Control and treated fibroblasts were resuspended in 500 μL of
25mMTris-HCl pH 7.5; 1mMDTT and 1% v/v glycerol buffer containing
1× protease inhibitor cocktail (Sigma-Aldrich). Samples were sonicated
on ice through 4 cycles of 20 pulses each, with 45 s rest between cycles.
The homogenates were centrifuged at 100,000 ×g for 1 h and the
protein concentration determined by BCA method (Thermo Scientific).
Soluble proteins present in a 20 μg aliquot were reduced using
4 mM dithiothreitol (Sigma-Aldrich) in 100 mM ammonium bicar-
bonate at 56 °C for 15min and then alkylated in 8mM iodoacetamide
(Sigma-Aldrich) for 15 min in the dark. Enzymatic digestion was
carried out at 37 °C for 18 h using 0.8 μg Sequencing Grade Modified
Trypsin (Promega) and the reaction was interrupted by acidification
with 10 μL acetic acid. Tryptic peptides were cleaned up using a
Strata C18-E cartridge (55 μm, Phenomenex), dried over speed vacu-
um and resuspended in 0.1% v/v formic acid.2.5. Mass spectrometry analysis: in solution digestion
For each sample, 3 μg of tryptic peptides were separated in a
UltiMate® 3000 UHPLC system (Thermo Scientific) equipped with a
C18 column (PepMap Acclaim RSLC — 75 nm × 15 cm, Thermo
Scientific) under mobile phase flow of 0.3 μL/min using a nonlinear
gradient (4 to 90% of 80% v/v acetonitrile and 0.1% v/v formic acid)
during 180 min. The eluted peptides were ionized in a ESI-nanospray
interface and analyzed in a Q-Exactive™ Hybrid Quadrupole-Orbitrap
instrument (Thermo Scientific) under the acquisition mode Full MS
followed by MS/MS. The following operating parameters were set: Full
MS resolution: 70.000; MS/MS resolution: 17,500; scan range: 300–
2000 m/z; 12 most abundant isotope patterns scanned; loop count:
10; isolation window: 2.0 m/z; ions exhibiting charge +2, +3 or +4;
dynamic exclusion: 60 s; positive ionization mode.
The Xcalibur v.3.0.63.3 and MaxQuant v.1.5.2.8 softwares [18] were
used for the acquisition and data analysis, respectively. Database
searches were performed using a UniProt Rattus norvegicus compilation
containing 30,091 sequences. Search parameters included: enzyme:
trypsin/P; carbamidomethylation of cysteine as fixed modification; ox-
idation ofmethionine andN-terminal acetylation as variable;maximum
missed cleavage sites: 2; mass tolerance: 4.5 ppm; isotope match toler-
ance: 2 ppm; minimum peak length: 2; False Discovery Rate (FDR) and
Peptide Sequence Match (PSM): 0.01;minimum ratio count: 2. Relative
abundance of proteins were obtained using Label-Free Quantification
(LFQ) provided by the LFQ intensity data (unique + razor peptides).
2.6. Statistical analyses and protein functional categorization
Statistical analysis was performed using the Graph Pad Prism soft-
ware v.6.01. For each exposure time to the PR-11 peptide, proteins
exhibiting at least two LFQ intensity data among the three biological
triplicates were regarded genuine identifications. These were subjected
to a t-test and the proteins with p b 0.01 were considered significantly
altered. Differentially expressed proteins were categorized using the
UniProtKB database (available at www.uniprot.org) according to their
biological functions.
2.7. Total protein extraction, affinity chromatography and in gel digestion
A liver protein extract from Wistar rat was obtained for use in
immobilized PR-11 affinity chromatography. Approximately 100 mg
tissue section was homogeneized in 1 mL of extraction buffer (50 mM
Tris-HCl pH 7.5; 100 mM NaCl) containing 1× protease inhibitor
cocktail (Sigma-Aldrich). Sample was sonicated on ice through 5 cycles
of 20 pulses each, with 45 s rest between cycles. The homogenate was
centrifuged at 20,000 ×g for 1 h and the protein concentration
determined by BCA method (Thermo Scientific).
Coupling of PR-11 peptide to the Sepharose 4B matrix was
performed as previously described [19]. Approximately 10 mg of total
proteins were loaded onto a 1 mL column containing immobilized PR-
11. The column was extensively washed with 50 mM Tris-HCl pH 7.5;
300 mM NaCl and 5 mMMgCl2 and the bound fraction recovered after
loading 1 mL of 50 μM PR-11. The collected samples were dialyzed in
10 mM ammonium acetate pH 7.4 and dried over speed vacuum.
Aliquots taken from the collected samples were analyzed under
denaturing conditions using 12% SDS-PAGE as classically described
[20] and the gel stained in silver nitrate.
Visualized bands from the bound fractionwere excisedmanually for
in gel digestion. The bands were destained in 0.5% w/v potassium ferri-
cyanide/10% w/v sodium thiosulfate and washed in 40% v/v ethanol/7%
v/v acetic acid. Disulfide bonds were reduced in 500 μL of 50mMDTT at
65 °C for 30 min and alkylated in 300 μL of 100 mM iodoacetamide at
room temperature for 1 h in the dark. Gel pieces were washed in
500 μL of 20 mM NH4HCO3/50% v/v acetonitrile for 3 × 20 min and
dried in a speed vacuum. Then, gel pieces were rehydrated in 20 μL of
Fig. 1. Volcano plots revealed similar distribution of down- and upregulated molecules
throughout the three timing points. A–C: Protein expression in fibroblasts exposed to
1 μM PR-11 during 2, 6 and 10 h measured by fold (±) and p value. Differentially
expressed proteins (p b 0,01) are exhibited above the dashed horizontal line. Proteins
detected only in untreated cells or exposed fibroblasts are displayed above fold infinity
(±). Median folds were obtained using the three independent biological triplicates.
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NH4HCO3. Trypsin digestion proceeded at 37 °C for 18 h. For each sam-
ple, the resulting peptides were recovered, dried over speed vacuum
and resuspended in 10 μL of 0.1% formic acid.
2.8. Mass spectrometry analysis: in gel digestion
Tryptic peptides fromeach bandwere loaded onto a UltiMate® 3000
UHPLC system (Thermo Scientific) equipped with a C18 column
(PepMap Acclaim RSLC— 75 nm× 15 cm, Thermo Scientific). A nonlin-
ear gradient was set to 4–90% of 80% v/v acetonitrile in 0.1% v/v formic
acid during 45 min under a flow rate of 0.3 μL/min. The eluted peptides
were ionized in a ESI-nanospray interface and analyzed in a Q-
Exactive™Hybrid Quadrupole-Orbitrap instrument (Thermo Scientific)
under the acquisition mode Full MS followed by MS/MS. The following
operating parameters were set: Full MS resolution: 70.000; MS/MS
resolution: 17.500; scan range: 300–2000 m/z; 10 most abundant
isotope patterns scanned; loop count: 10; isolation window: 2.0 m/z;
ions exhibiting charge+2,+3 or+4; dynamic exclusion: 90 s; positive
ionization mode.
The Xcalibur v.3.0.63.3 and Proteome Discoverer v.1.5.2.8 softwares
were used for acquisition and data analysis, respectively. Database
searches were performed using a UniProt Rattus norvegicus reviewed
compilation containing 9584 sequences. Search parameters included:
enzyme: trypsin/P; carbamidomethylation of cysteine as fixed modifi-
cation; oxidation of methionine and N-terminal acetylation as variable;
onemiscleavage site;mass tolerance: 10 ppm and 0.1 Da toMS andMS/
MS, respectively; peptidemass: 300–4000Da; high peptide confidence;
at least 3 unique peptides per identified protein; quantification by area
detector. A minimum of 10% contribution to the total area detected in
each band was required to assign a protein identity.
3. Results
3.1. Label-free quantitative proteomics
Shotgun analyses of the soluble fractions, from cultured fibroblasts
exposed to 1 μM PR-11 for 2, 6 and 10 h, revealed a total of 1941 mole-
cules confidently identified in at least one of the three timing points
(Supplementary Table 1). Using the LFQ intensity data, a Spearman
correlation analysis was conducted to assess sample reproducibility in
the three independent biological replicates. As shown in Supplementary
Fig. 2, correlation coefficients varied from 0,917 to 0,980, indicating that
samples were suitable for downstream comparative analyses. Then, by
applying a stringent criteria for quantification of differentially expressed
proteins (p b 0,01), it was found 57, 67 and 59 molecules significantly
altered in PR-11 exposed fibroblasts treated for 2, 6 and 10 h, respec-
tively (Fig. 1). After 2 h exposure, 26 proteins were downregulated,
whilst 31 were at increased levels relative to untreated cells. At 6 h
post exposure, both the number of down- and upregulated molecules
increased to 29 and 38, respectively. At 10 h, 2/3 of the differentially
expressed proteins (39) were downregulated and the remaining (20)
was found at increased levels. Of note, according to our statistic criteria
for quantification the differentially expressed proteins were mostly
unique to each time point, as shown in Fig. 2. Although 1388 (71,5% of
the total) proteins were commonly identified in the three time points
(Fig. 2A), only seven shared identities appeared differentially expressed
(Fig. 2B).
3.2. Categorization of differentially expressed proteins
All 175 differentially expressed proteins (p b 0,01) were classified
according to their biological function into 9 distinct categories using
UniProtKB annotation, Fig. 3 and Table 1. Over 50% of the categorized
proteins are involvedwith cell signalling (74) and transcription/transla-
tion (33). Out of 59 differentially expressed proteins found at 2 h, 17were unique from untreated cells whilst 27 were found in PR-11
exposed fibroblasts. At this time point, proteins exhibiting the most
altered levels were mitochondrial fission 1 protein (0,47 fold – cell
signalling), the translation initiation factor eiF2B subunit delta (1,59
fold – transcription/translation) and nucleoporin 85 kDa (1,95 fold –
structural).
At 6 h post exposure, out of 67 molecules significantly altered, 14
and 33 proteins were found only in control or treated fibroblasts,
Fig. 2. Fibroblasts exposed to the PR-11 peptide display time-dependent proteomic alterations. A: In total, 1388 or 71,5% of the proteins were identified in the three timing points. B: Only
seven shared identities appeared differentially expressed among all exposure times.
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proteins (29), highlighting the downregulation of vesicle trafficking 1,
SEC23 homolog B (0,65 fold), RACK1 and SEC24 homolog D (0,66 fold)
and the upregulation of CGR11 (1,83 fold), R-ras (1,48 fold) and 14–3-
3 protein beta/alpha (1,46 fold). Transcription/translation was the
second category containing a significant number of altered proteins. In
particular, decreased levels for 4 quantified proteins – acinus, 40S
ribosomal protein S4, hnRPN D and the translation elongation factor
eEF1B2 (0,75; 0,75; 0,77 and 0,81) – were observed. In the group of
structural proteins, mitochondrial inner membrane protein (0,65 fold)
and transgelin-2 (1,25 fold) were the two molecules showing the
most pronounced alterations.
After 10 h exposure, 19 out of 39 significantly downregulated pro-
teins were found only in untreated fibroblasts, whilst 16 out of 20
from PR-11 exposed cells exhibited increased levels. Exportin-2 (0,56
fold), ataxin-10 (0,57 fold) and cysteine and glycine-rich protein 1
were the most altered cell signalling representatives. Within transcrip-
tion/translation category, out of 11 molecules differentially expressed,
SFRS7 was the unique quantified protein in both treated and untreated
cells (1,17 fold).
3.3. Identification of PR-11 binding proteins
A liver protein extract from Wistar rat was loaded onto an
immobilized PR-11 affinity chromatography. Unspecific binding was ad-
dressed by applying a stringent washing step (300 mM NaCl). This pro-
cedure intended to disrupt electrostatic interactions and removal of
bound proteins with low affinity to the column. After exhaustive
washing steps, one column volume was dried to completion and
analyzed by SDS-PAGE. Silver staining on the gel revealed no protein
band (Fig. 4, FPE: fraction prior to elution). Elution of bound material
was performed using 50 μM PR-11. 12% SDS-PAGE allowed the
visualization of 9 bands in the eluted fraction (Fig. 4, EF: eluted fraction).
These were successfully identified by mass spectrometry (Table 2). Of
particular interest, band 7 contained a dominant constituent (relative
area detector: 96.2%) identified as the gC1qR protein. 78 kDa glucose-
regulated protein (band 2), ornithine carbamoyltransferase (band
6) and carbonic anhydrase 3 (band 8) were also prominent in their
respective bands contributing to at least 65%of the relative area detected.
4. Discussion
In this study we seek to investigate the soluble proteome alterations
caused by exposure of fibroblasts to the peptide PR-11 to gain furtherunderstanding of its biological functions. Knowledge of its angiogenic
and anti-inflammatory properties makes PR-11 of particular interest
for specific processes, such as wound repair via topic administration or
infused through different routes. In the present work, micromolar
concentration was employed to account for PR-11 peptide degradation
or limited absorption. The choice of themicromolar range has been also
reported by other studies that used PR-39 derived molecules in cell
cultures or distributed through tissues [15,21].
By combining improved resolution for chromatographic separation
of peptides and increased accuracy of modern mass spectrometry in-
strumentation [22,23] we were able to identify and quantify almost
two thousand soluble proteins, using a label-free shotgun approach.
The statistical analysis was performed as described by the inventors of
the MaxQuant software [18], in which a standard t-test is employed.
This test was used to measure minor alterations in protein levels in
this first global analysis of proteome alterations induced by the PR-11
peptide. A more stringent condition of analysis could mask some real
and existing alterations. The detected protein abundance differed in
five orders of magnitude, allowing for quantitative evaluation of prote-
omic alterations among major and minor components of our protein
preparation. The volcano plots displayed a similar distribution of up-
and downregulated molecules throughout the three timing points.
Nevertheless, analysis of the Venn diagram demonstrates unique
proteome alterations caused by PR-11 at the different sampling times,
relative to the respective non-exposed control cells, possibly reflecting
cell-stage specific proteins altered by the treatment.
In total, 175 molecules were found at increased or decreased levels
over the 10 h experiment. Protein categorization, using biological
function, revealed that over 40% is represented by molecules involved
in cell signalling. In fact, PR-39 and PR-11 are known to interfere with
important cellular pathways such as the hypoxia-inducible factor 1-α
(HIF-1α) [14] and nuclear factor kappa B (NF-κB) [15,16]. Here we
proposed to initiate the discussion of our findings in the context of
these two signalling events to give mechanistic insights into the
putative roles of PR-11 in cell biology.
- Hypoxia-inducible factor-1 α pathway
The peptides PR-39 and PR-11 are able to stimulate angiogenesis
both in vitro and in vivo [16,17]. Studies have shown that the transient
expression of PR-39 in cardiomyocytes resulted in increased vasculari-
zation, reduced resistance to blood flow and myocardial hypertrophy
[14,24,25]. These effects are partially explained by decreased
proteasomal degradation of HIF-1α, a molecule known to regulate the
expression of several genes related to angiogenesis, including VEGF
Fig. 3. Functional classification of differentially expressed proteins from cultured fibroblasts exposed to 1 μM PR-11 for 2, 6 and 10 h. A-C: Proteins significantly altered (p b 0,01) were
categorized according to their biological function into 9 distinct categories using UniProtKB annotation. Measurements of down- or upregulation of proteins in each category are
indicated by numbers in parentheses, respectively. Of note, over half of the classified proteins are associated with cell signalling (74) and transcription/translation (33).
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Table 1
Classification of differentially expressed proteins (p b 0,01) according their biological function (UniProtKB annotation).
2 h
ID UniProtKB Protein Gene PR-11/Control
ratio






Q02401; A9CMC8 Lactase-phlorizin hydrolase Lct +∞ 2,45E-05 2 1,3
Cell signalling
P0C1X8; F1LRI7 AP2-associated protein kinase 1 Aak1 −∞ 2,24E-05 3 4,6
D3ZAX5 Calcium homeostasis endoplasmic reticulum protein
(Predicted)
Cherp −∞ 3,09E-05 3 4,5
D3ZHC4 Heme binding protein 2 (Predicted), isoform CRA_b Hebp2 −∞ 3,18E-08 3 17,7
G3V7J2; Q4V8C7 Interferon-inducible double-stranded RNA-dependent
protein kinase activator A
Prkra −∞ 2,22E-03 4 21,1
A0A096MJY1 Protein Gpc6 Gpc6 −∞ 7,43E-06 4 10,1
D3ZQC6 Protein Ubr1 Ubr1 −∞ 1,04E-06 6 6,8
A0A0G2K2U5; D3ZUQ0 RILP-like protein 1 Rilpl1 −∞ 8,30E-08 6 19,6
Q498D8 Ring-box 1, E3 ubiquitin protein ligase Rbx1 −∞ 9,57E-03 3 25
P84817 Mitochondrial fission 1 protein Fis1 0,47 5,31E-04 5 42,1
F1LVV4 Regulator of chromosome condensation 2 Rcc2 0,80 9,83E-04 9 26
G3V9T7 ASNA1 ATPase Asna1 0,82 8,11E-03 8 34,2
D3ZH75 AKT1 substrate 1 (Proline-rich) (Predicted), isoform CRA_d Akt1s1 +∞ 1,76E-04 3 19,1
P14668 Annexin A5 Anxa5 +∞ 1,05E-05 1 7,8
Q62865 cGMP-inhibited 3,5-cyclic phosphodiesterase A Pde3a +∞ 1,42E-04 2 2,9
B1WBY1 Cul1 protein Cul1 +∞ 1,50E-05 9 16,4
Q923V4 F-box only protein 6 Fbxo6 +∞ 1,80E-06 4 16,5
P60517; Q0VGK0; P60522;
F1M1J6; A0A0G2JU55
Gamma-aminobutyric acid receptor-associated protein Gabarap +∞ 2,08E-10 2 15,4
Q91V33 KH domain-containing, RNA-binding, signal transduction-associated
protein 1
Khdrbs1 +∞ 8,12E-06 4 12
Q68FQ9 LanC lantibiotic synthetase component C-like 2 Lancl2 +∞ 3,79E-05 4 14,4
Q6NX65 Programmed cell death protein 10 Pdcd10 +∞ 3,12E-04 3 21,9
B0BN72 Protein FAM195B Mcrip1 +∞ 5,91E-04 3 41,2
Q3MIF1; G3V8E4 Protein Ubfd1 Ubfd1 +∞ 2,07E-04 3 14,1
B2RZ96 Ubiquitin Conjugating Enzyme E2 R2 Ube2r2 +∞ 1,21E-03 3 14,7
Lipid metabolism
D3ZPU3; Q6P7R8 Very-long-chain 3-oxoacyl-CoA reductase Hsd17b12 −∞ 4,27E-06 2 10,3
Q5BK81 Prostaglandin reductase 2 (PTGR2) Ptgr2 0,82 1,61E-03 8 40,2
B0BNM9 Glycolipid transfer protein Gltp +∞ 8,71E-06 2 12,9
Nucleotide/phosphate metabolism
Q920P6 Adenosine deaminase Ada −∞ 2,66E-04 9 31,5
Q06647 ATP synthase subunit O, mitochondrial Atp5o −∞ 2,89E-05 3 24,4
A0A0G2K478; D3ZDE4 Deoxyguanosine kinase (Predicted),
isoform CRA_b
Dguok −∞ 8,29E-03 4 20,6
F7EPZ4 Protein Dis3 Dis3 −∞ 7,04E-06 6 7,5
Protease
P62198 26S protease regulatory subunit 8 Psmc5 0,77 2,38E-03 19 57,9
D3ZHQ1 Dipeptidylpeptidase 8 (Predicted), isoform CRA_a Dpp8 +∞ 1,04E-03 4 6,6
Q5PPG2; Q9R0J8 Legumain Lgmn +∞ 1,82E-03 2 9,9
Q6AYR8 Secernin-2 Scrn2 +∞ 2,33E-03 4 16,8
Protein folding
B2GV92; P83868 Prostaglandin E synthase 3 (p23) Ptges3 0,82 4,80E-03 8 51,2
Q52KJ9 Protein Tmx1 Tmx1 +∞ 1,53E-04 4 20,5
Structural
D3ZCI9 Protein Myl10 Myl10 -∞ 2,59E-04 2 7,5
V9GZ85; P63259;
A0A0G2K3K2
Actin, cytoplasmic 2 Actg1 1,08 6,86E-03 32 81,3
Q4QQS8 Nucleoporin 85 kDa Nup85 1,95 4,38E-03 7 13,4
D4A1B2 Arpin protein Arpin +∞ 7,01E-07 5 29,6
A0A0G2KAJ7 Collagen alpha-1(XII) chain Col12a1 +∞ 7,52E-04 8 4
Transcription/translation
M0RA26; Q71TY3; P24051 40S ribosomal protein S27 Rps27 −∞ 5,97E-06 2 25
Q9QYU2 Elongation factor Ts, mitochondrial Tsfm −∞ 1,15E-04 5 30,2
Q6AYL5 Splicing factor 3B subunit 4 Sf3b4 −∞ 4,05E-03 3 14,4
Q5RKI1; A0A0G2K8B7 Eukaryotic initiation factor 4 A–II Eif4a2 0,67 3,36E-03 11 45
G3V6F5; Q8CGS5 Zinc phosphodiesterase ELAC protein 2 Elac2 0,81 6,78E-03 9 15,2
Q5M827 Pirin Pir 0,85 2,49E-03 4 16,8
A0A0H2UHV4; M0R7Z0;
B2GUV7
Eukaryotic translation initiation factor 5B Eif5b 1,21 1,77E-03 12 15,2
A0A096MIS3; Q63186 Translation initiation factor eIF-2B subunit delta Eif2b4 1,59 2,08E-03 6 19,6
P62250 40S ribosomal protein S16 Rps16 +∞ 1,83E-03 5 32,9
G3 V992 General transcription factor II E, polypeptide 1 (alpha subunit) Gtf2e1 +∞ 1,24E-04 2 5,5
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Table 1 (continued)
2 h
ID UniProtKB Protein Gene PR-11/Control
ratio





B5DEK0 Regulation of nuclear pre-MRNA domain containing 1B Rprd1b +∞ 1,85E-06 5 26,1
D3ZCD7; D3ZL21 TP53 regulating kinase Tp53rk +∞ 3,74E-06 3 17,6
Other processes
Q5BJP9 Phytanoyl-CoA dioxygenase domain-containing protein 1 Phyhd1 +∞ 7,22E-03 7 36,1
Q6AYT5 Protein-glutamate O-methyltransferase Armt1 +∞ 2,32E-08 5 15,5
Q642A4 UPF0598 protein C8orf82 homolog C8orf82 +∞ 1,50E-04 2 14,2
6 h
Carbohydrate metabolism
D3ZY02 ATH1, Acid Trehalase-Like 1 Athl1 0,71 5,49E-03 8 16,6
Q5BJY6 N-acetylglucosamine-6-phosphate deacetylase Amdhd2 +∞ 2,96E-04 3 10,3
Cell signalling
P0C1X8; F1LRI7 AP2-associated protein kinase 1 Aak1 −∞ 1,85E-06 3 4,6
Q6P7Q1 BRCA1-A complex subunit BRE Bre −∞ 2,83E-04 2 7,3
A0A0G2JYN0; Q5U2M6 DDB1- and CUL4-associated factor 8 Dcaf8 −∞ 6,30E-03 6 15,9
F1LP57 Mitogen-Activated Protein Kinase Kinase 4 Map2k4 −∞ 6,00E-04 3 11,6
Q5U204 Regulator complex protein LAMTOR3 Lamtor3 −∞ 2,30E-04 3 37,1
G3V9H0; P50904 Ras GTPase-activating protein 1 Rasa1 −∞ 1,59E-03 7 10,4
Q5HZY0 UBX domain-containing protein 4 Ubxn4 −∞ 1,32E-03 2 6,9
D3ZCT7 Sec23 homolog B, coat complex II component Sec23b 0,65 4,92E-04 10 18,5
A0A096MKH2; Q4KM55 Vesicle trafficking 1 Vta1 0,65 3,84E-03 7 30,7
P63245; A0A0G2JZE6 RACK1 (Receptor of activated protein C kinase 1) Rack1 0,66 7,74E-04 15 68,5
G3V9S9 SEC24 homolog D, COPII coat complex component Sec24d 0,66 1,91E-03 16 24,4
Q4KLJ8 PDCL3 (Phosducin-like protein 3) Pdcl3 0,71 4,09E-03 6 27,9
Q4QQR9; F1LNE5 Protein MEMO1 Memo1 0,74 8,94E-03 14 75,8
Q68FW9 COP9 signalosome complex subunit 3 Cops3 0,84 8,38E-03 10 35,9
P35213 14–3-3 protein beta/alpha Ywhab 1,46 5,14E-03 10 55,3
D3Z8L7 Ras-related protein R-Ras Rras 1,48 3,85E-04 5 31,7
P97586; A0A0A0MXV3 CGR11 (cell growth regulatory gene 11 protein) Cgref1 1,83 3,64E-04 4 19,9
F1LM60 ArfGAP With RhoGAP Domain, Ankyrin Repeat And PH Domain 1 Arap1 +∞ 1,79E-04 4 4,7
Q712J3; Q496Z1 Bicaudal D homolog 2, isoform CRA_a Bicd2 +∞ 1,20E-04 7 10,9
O35826; A0A0G2K7T2 Bifunctional UDP-N-acetylglucosamine
2-epimerase/N-acetylmannosamine kinase
Gne +∞ 6,81E-03 7 15,2
G3V8Z9; F1MAA2 COP9 Signalosome Subunit 7 A Cops7a +∞ 5,67E-03 5 25,8
G3V927; P97839 Discs, large homolog-associated protein 4 Dlgap4 +∞ 1,59E-04 6 7,5
B4F7C7 Heme Binding Protein 1 Hebp1 +∞ 1,75E-03 2 17,9
F1M9B2 Insulin-like growth factor binding protein 7, isoform CRA_b Igfbp7 +∞ 1,60E-04 4 23,5
Q91V33 KH domain-containing, RNA-binding, signal
transduction-associated protein 1
Khdrbs1 +∞ 8,08E-05 4 12
Q9QX69 LanC-like protein 1 Lancl1 +∞ 1,07E-04 7 26,6
A0A0G2K0P2; O70436;
G3 V603; O54835
Mothers against decapentaplegic homolog Smad2 +∞ 2,21E-04 2 5,8
A0A0G2K7P7; A0A0G2K459 Protein Mtch2 Mtch2 +∞ 3,31E-04 3 22
Q5U1Z2 Trafficking protein particle complex subunit 3 Trappc3 +∞ 1,67E-03 4 22,2
Lipid metabolism
O88637 Ethanolamine-phosphate cytidylyltransferase Pcyt2 +∞ 5,38E-03 1 3,2
Q6IMY6; Q64194 Lysosomal acid lipase/cholesteryl ester hydrolase Lipa +∞ 4,92E-04 3 11,6
Nucleotide/phosphate metabolism
Q3MIE9 Spermine Synthase Sms +∞ 1,02E-03 8 28,4
Protease
Q6P9V7; Q63797 Proteasome activator complex subunit 1 Psme1 0,70 1,83E-03 14 50,2
Protein folding
Q6AY58 B-cell receptor-associated protein 31 Bcap31 1,54 9,77E-03 3 11,4
P63036 DnaJ homolog subfamily A member 1 Dnaja1 +∞ 1,01E-04 6 23,7
A0A0G2K093; O35162 Heat shock 70 kDa protein 13 Hspa13 +∞ 1,23E-03 6 18,1
G3 V828 Protein Cnpy3 Cnpy3 +∞ 3,28E-06 4 17
F1M8A5; Protein Hypk Hypk +∞ 9,18E-04 4 42,6
B2GUZ7 Tubulin Folding Cofactor C Tbcc +∞ 1,31E-05 4 19,4
Structural
P16636 Protein-lysine 6-oxidase Lox −∞ 9,65E-03 2 8,3
A0A0G2K6B2; A0A0G2K1P8 TRIO And F-actin binding protein Triobp −∞ 4,12E-03 8 15
A0A140TAG5; Q3KR86;
A0A0G2JVH4
Mitochondrial inner membrane protein Immt 0,65 2,23E-03 12 30,6
G3V6S0; A0A0G2K8W9;
A0A0G2JZY6
Spectrin Beta, Non-Erythrocytic 1 Sptbn1 0,85 3,77E-03 80 44,7
Q5XFX0 Transgelin-2 Tagln2 1,25 9,77E-03 16 84,4
(continued on next page)
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B2GV74 Kinesin light chain 2 (Predicted), isoform CRA_b Klc2 +∞ 3,87E-04 4 9
B1WBY6; G3V6M8 Nucleoporin 37 kDa Nup37 +∞ 9,17E-03 4 18,8
Q66HC5 Nucleoporin 93 kDa Nup93 +∞ 4,83E-04 3 8,3
D3ZNS1; A0A0G2JV32; A0A0G2JTS5;
Q63312
Pleckstrin homology-like domain family B member 1 Phldb1 +∞ 4,97E-04 9 8,3
Transcription/translation
A0A0G2JVA7; Q6VV72; B5DF60 Eukaryotic translation initiation factor 1 A Eif1a −∞ 1,43E-04 3 21,5
Q5M965 Probable tRNA(His) guanylyltransferase Thg1l −∞ 1,57E-04 3 14,4
G3V6S8 Serine/arginine-rich splicing factor 6 Srsf6 −∞ 9,69E-04 6 15
X1WI37; P62703; A0A0H2UHX3;
D3ZX01
40S ribosomal protein S4 Rps4x 0,75 4,14E-03 7 29,8
E9PST5 Acinus (apoptotic chromatin condensation inducer 1) Acin1 0,75 6,40E-03 15 15,6
Q9JJ54 hnRPN D (heterogeneous nuclear ribonucleoprotein D0) Hnrnpd 0,77 5,89E-03 13 34,6
B5DEN5 Eukaryotic translation elongation factor 1 beta 2 Eef1b2 0,81 9,69E-04 9 61,8
M0RA26; Q71TY3; P24051 40S ribosomal protein S27 Rps27 +∞ 9,94E-07 2 25
B1WBQ0; O08837 CDC5L_RAT Cell division cycle 5-like protein Cdc5l +∞ 3,47E-04 3 7
A0A0G2JTY6; F1LRK4 G-Rich RNA Sequence Binding Factor 1 Grsf1 +∞ 3,78E-03 5 19,7
D3ZFB2 LUC7 Like 3 Pre-MRNA Splicing Factor Luc7l3 +∞ 1,70E-03 3 8,4
D3ZUL8 Zinc Finger CCHC-Type Containing 8 Zcchc8 +∞ 3,60E-03 4 9,6
Other processes
Q5XIT9 Methylcrotonoyl-CoA carboxylase beta chain, mitochondrial Mccc2 −∞ 5,88E-04 6 16,3
Q6AYT5 Protein-glutamate O-methyltransferase Armt1 −∞ 3,25E-04 5 15,5
B0K020 CDGSH iron-sulfur domain-containing protein 1 Cisd1 +∞ 4,75E-03 2 25,9
A0A0G2K1N9 Selenoprotein O Selo +∞ 1,04E-06 3 6,8
Q6AY72 UPF0449 protein C19orf25 homolog C19orf25 +∞ 9,36E-06 3 54,1
10 h
Carbohydrate metabolism
P43424 Galactose-1-phosphate uridylyltransferase Galt −∞ 2,75E-05 3 9,5
Q02401; A9CMC8 Lactase-phlorizin hydrolase Lct +∞ 2,13E-03 2 1,3
Cell signalling
B5DFH4; A0A0G2K950 3′-Phosphoadenosine 5′-Phosphosulfate Synthase 2 Papss2 −∞ 1,48E-04 3 6,2
P62332 ADP-ribosylation factor 6 Arf6 −∞ 4,64E-04 3 24,6
B2RYJ3 Cullin 4 A Cul4a −∞ 4,49E-04 6 9,2
D4A0W7 Fibronectin Type III Domain Containing 3B Fndc3b −∞ 1,75E-03 7 8,5
Q562C6 Leucine zipper transcription factor-like protein 1 Lztfl1 −∞ 1,06E-04 5 24,7
Q5BJX0 N-terminal Xaa-Pro-Lys N-methyltransferase 1 Ntmt1 −∞ 2,05E-03 4 24,7
A0A0G2QC06; Q4FZX7 Signal recognition particle receptor subunit beta Srprb −∞ 1,01E-05 9 11,2
Q5I0H3 Small ubiquitin-related modifier 1 Sumo1 −∞ 1,97E-04 4 42,6
D4A6C6; A0A0U1RRU5 TGF-beta activated kinase 1/MAP3K7 binding protein 1 Tab1 −∞ 6,46E-06 4 9,6
D3ZPR0 Exportin-2 Cse1l 0,56 8,28E-04 17 24,5
Q9ER24 Ataxin-10 Atxn10 0,57 8,58E-03 15 42,3
M0RA08 Perilipin Plin3 0,61 3,76E-03 15 55,9
Q80U96 Exportin-1 Xpo1 0,63 2,93E-03 23 29,9
Q9EQX9 UBE2N (Ubiquitin-conjugating enzyme E2 N) Ube2n 0,72 2,40E-03 7 65,1
A0A0G2K0X9; G3 V699; Q9Z2Q1 Protein transport protein Sec31A Sec31a 0,73 4,24E-04 38 38,2
A1L1M0; P27791 PKA C-alpha (cAMP-dependent protein kinase catalytic subunit
alpha)
Prkaca 0,74 4,99E-03 12 41,9
Q5U211 Sorting nexin-3 Snx3 0,74 9,60E-03 6 35,2
Q99J82 Integrin-linked protein kinase IlK 0,76 6,14E-03 9 21,9
Q5XI34 Protein Phosphatase 2 Regulatory Subunit A, Alpha Ppp2r1a 0,78 6,51E-03 28 58,6
F1 M779; P11442 Clathrin heavy chain 1 Cltc 0,82 6,31E-03 77 57,3
P47875 Cysteine and glycine-rich protein 1 Csrp1 1,41 5,82E-03 10 60,1
F1M6A8; A0A0G2JXD7; Q63484 RAC-gamma serine/threonine-protein kinase Akt3 +∞ 1,58E-05 2 5,8
D4A511 Signal recognition particle 9 kDa protein Srp9 +∞ 1,06E-03 2 25,6
A0A0G2K2V2; G3V9N8; P52303 AP complex subunit beta Ap1b1 +∞ 5,33E-03 11 17,7
Lipid metabolism
B0BNM9 Glycolipid transfer protein Gltp −∞ 9,30E-04 2 12,9
F8WG67; Q64559 Cytosolic acyl coenzyme A thioester hydrolase Acot7 0,81 6,57E-03 7 29,8
D3ZKG1 Methylmalonyl-CoA Mutase Mut +∞ 8,12E-05 4 5,8
Nucleotide/phosphate metabolism
D4A8A0 CAD trifunctional protein Cad 0,78 8,45E-03 22 14,9
Protease
Q99ML5 Prenylcysteine oxidase Pcyox1 −∞ 1,52E-04 6 19,4
Q07009 Calpain-2 catalytic subunit Capn2 0,85 6,40E-03 36 61,1
P18420 Proteasome subunit alpha type-1 Psma1 1,26 2,07E-03 14 61,6
Structural
Q08163 CAP1 (Adenylyl cyclase-associated protein 1) Cap1 0,76 3,16E-03 26 73,6
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ID UniProtKB Protein Gene PR-11/Control
ratio





F1LN42 Tensin 1 Tns1 0,77 2,72E-03 31 27,9
D3ZU74; Q6AZ35; G3V9V3;
Q62871
Cytoplasmic dynein 1 intermediate chain 2 Dync1i2 0,91 5,08E-03 19 48,2
G3 V624 Coronin 1C Coro1c 1,19 8,98E-05 16 38,4
D4AC70 Collagen Type VIII Alpha 1 Col8a1 +∞ 5,75E-03 4 6,7
A0A0G2K2Z0; F1LT71 Echinoderm microtubule associated protein like 4 Eml4 +∞ 1,11E-07 3 4,5
F1LYQ8 FERM, RhoGEF and pleckstrin domain-containing protein 1 Farp1 +∞ 6,59E-06 5 5,6
Transcription/translation
Q04931 FACT complex subunit SSRP1 Ssrp1 −∞ 1,03E-06 6 10
D3ZFB2 LUC7 like 3 pre-MRNA splicing factor Luc7l3 −∞ 2,89E-03 3 8,4
D4AE49 Ski2 Like RNA Helicase 2 Skiv2l2 −∞ 6,89E-04 6 7
Q5M7V8 Thyroid hormone receptor-associated protein 3 Thrap3 −∞ 2,27E-04 10 13,7
D4A720 SFRS7 (serine/arginine-rich splicing factor 7) Srsf7 1,17 6,97E-03 7 28,6
Q5XI97 Alanyl-tRNA editing protein Aarsd1 Aarsd1 +∞ 7,78E-03 4 15
G3V8Y5 DNA-directed RNA polymerase subunit beta Polr2b +∞ 2,82E-03 7 8,5
D3ZZ62 Exportin, tRNA (Nuclear export receptor for tRNAs)
(Predicted), isoform CRA_a
Xpot +∞ 4,63E-05 6 10
D4A7F2 Protein Mycbp Mycbp +∞ 4,54E-06 4 55,3
Q4QR99; A0A0H2UHF3 Queuine tRNA-ribosyltransferase Qtrt1 +∞ 3,48E-04 3 10,2
P86252; F1LPS8 Transcriptional activator protein Pur-alpha (Fragments) Pura +∞ 3,33E-03 3 42
Other processes
G3V8P2; Q8VHT6 Arsenite methyltransferase As3mt −∞ 1,67E-03 2 8,4
D3ZSR7 Protein Ccdc102a Ccdc102a −∞ 5,51E-04 4 10
D3ZII8 SMYD Family Member 5 Smyd5 −∞ 1,08E-04 3 12
B4F7E0; Q2A121; A0A0G2K675 Alpha-ketoglutarate-dependent dioxygenase FTO Fto 0,66 2,95E-03 9 27,1
A0A0G2JY07 Minichromosome maintenance complex component 5 (CDC46) Mcm5 0,71 6,17E-03 10 18,8
D3ZIE9 Aldehyde Dehydrogenase 18 Family Member A1 Aldh18a1 0,85 2,77E-03 32 53,1
D3Z8Q7 Protein Fam96b Fam96b +∞ 2,12E-03 2 26,1
Q6AYT5 Protein-glutamate O-methyltransferase Armt1 +∞ 2,01E-03 5 15,5
Ratio N 1 corresponds to an increase in abundance, whereas b1 indicates decreased levels. Proteins identified only in untreated cells or exposed fibroblasts aremarked as fold infinity (±).
Fig. 4. 12% SDS-PAGE analysis of the immobilized PR-11 affinity chromatography. SM:
starting material; UF: unbound fraction; EF: eluted fraction; FPE: fraction prior to
elution. The specific displacement is shown by eluted fraction at low concentration of
PR-11 (50 μM) and absence of unbound proteins at fraction prior to elution. Identified
proteins in eluted fraction are in Table 2. Silver staining.
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this context, at 6 h exposure we found decreased expression of RACK1
(receptor for activated C kinase), which mediates ubiquitin-dependent
proteasomal degradation of HIF-1α [26], consequently allowing for
sustained cellular levels of this factor to favour angiogenesis. Our find-
ings also revealed downregulation of hnRPN D (heterogenous nuclear
ribonucleoprotein D), which is in agreementwith the angiogenic effects
of PR-11. Overexpression of hnRPN D in macrophages leads to de-
creased levels of endogenous VEGF, through its binding to the 3´-UTR
of VEGFmRNA [27].We also hypothesize that the angiogenic promoting
effects of PR-11 are unlikely associated to VEGFR-2 activation. At least
two observations in this study support this hypothesis: downregulated
levels of PDCL3 (phosducin-like 3) and increased expression of R-ras.
The former is a chaperone whose activity is associated to high expres-
sion levels of VEGFR-2 [28,29], whilst R-ras is a signalling molecule
that prevents internalization of this receptor [30].
- Nuclear factor kappa B pathway
The NF-κB protein family members are transcription factors
responsible for regulation of expression of several genes, including
those encoding cytokines and plasma membrane receptors. Therefore,
their roles in both innate and adaptive immune responses as well as in
inflammatory processes have been established [31,32]. In particular,
abolishing proteasomal degradation of IκB, an inhibitor of NF-κB, by the
peptides PR-11 and PR-39 leads to decreased expression of NF-κB depen-
dent pro-inflammatory proteins such as VCAM-1 (vascular cell adhesion
molecule-1) and ICAM-1 (intercellular adhesion molecule-1) [15,16]. In
this context, after 10 h exposure we found lower levels of PKA C-alpha,
a catalytic subunit of protein kinase A, involved in in vitro activation
and nuclear translocation of NF-κB in unstimulated murine cells [33].
Corroborating this finding, at the same time point decreased levels of
ILK (integrin-linked kinase) [34] and UBE2N (a ubiquitin-conjugating
Table 2
PR-11 binding proteins recovered by affinity chromatography.










1 P07756 Carbamoyl-phosphate synthase [ammonia], mitochondrial Cps1 16,9 19 (19) 34,0 164,5
P48721 Stress-70 protein, mitochondrial Hspa9 27,7 13 (13) 20,4 73,8
P04762 Catalase Cat 19,9 8 (8) 20,0 59,7
P00884 Fructose-bisphosphate aldolase B Aldob 12,6 3 (3) 10,9 39,6
2 P06761 78 kDa glucose-regulated protein Hspa5 47,1 30 (28) 73,1 72,3
P48721 Stress-70 protein, mitochondrial Hspa9 29,5 14 (14) 23,2 73,8
3 P02770 Serum albumin Alb 56,6 32 (32) 51,6 68,7
P04762 Catalase Cat 45,9 20 (20) 21,7 59,7
4 P10719 ATP synthase subunit beta, mitochondrial Atp5b 36,7 14 (14) 20,2 56,3
P04764 Alpha-enolase Eno1 46,3 12 (12) 15,3 47,1
P18418 Calreticulin Calr 9,6 3 (3) 10,9 48,0
5 P00507 Aspartate aminotransferase, mitochondrial Got2 9,5 3 (3) 58,8 47,3
O09171 Betaine–homocysteine S-methyltransferase 1 Bhmt 10,6 3 (3) 41,2 44,9
6 P00481 Ornithine carbamoyltransferase, mitochondrial Otc 39,8 12 (12) 71,4 39,9
P07824 Arginase-1 Arg1 26,3 7 (7) 10,8 35,0
7 O35796 Complement component 1 Q subcomponent-binding
protein, mitochondrial
C1qbp 31,9 5 (5) 96,2 31,0
8 P14141 Carbonic anhydrase 3 Ca3 54,6 10 (10) 65,7 29,4
P04904 Glutathione S-transferase alpha-3 Gsta3 18,6 4 (4) 17,3 25,3
9 P08010 Glutathione S-transferase Mu 2 Gstm2 61,9 16 (16) 44,0 25,7
P04905 Glutathione S-transferase Mu 1 Gstm1 45,4 13 (13) 31,4 25,9
O35244 Peroxiredoxin-6 Prdx6 56,7 11 (11) 17,2 24,8
Relative area detector (%) was obtained by dividing the area of given protein by the total area detected for all proteins identified in that band.
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regulation of the NF-κB pathway through distinct mechanisms.
There is only one published work describing the effects of the PR-11
peptide to culture cells [36]. The authors have demonstrated decreased
expression of VCAM-1 in endothelial cells exposed to 1 μM PR-11. The
cells were previously stimulated with TNF- α and the protein VCAM-1
detected by western blotting. Although this protein has not been
identified as differentially expressed in our study, other three proteins
whose transcription is NF-κB dependent were found to be differentially
expressed (e.g., PKA C-alpha, ILK and UBE2N) in agreement with the
anti-inflammatory effect attributed to the PR-11 peptide.
Differentially expressed proteins shown to have a role in oncogene-
sis were found for the three timing points. At 2 h, decreased levels of
ASNA1, prostaglandin E synthase 3 (p23) and prostaglandin reductase
2 (PTGR2) were observed. Reduced expression of ASNA1, an ATPase
required to insertion of tail-anchored proteins to the endoplasmic
reticulum, is associated to inhibition of cell growth and increased
apoptosis in melanoma cells [37]. The co-chaperone p23 is a subunit
of the Hsp90 complex shown to be upregulated in several cancers,
mainly in metastatic cells [38–40]. As for the prostaglandin E2 metabo-
lism, the knockdown of PTGR2 suppressed cell growth and induced
apoptosis in gastric cancer [41]. At 6 h post exposure, downregulation
of MEMO1 (mediator of ErbB2-driven cell motility 1) also suggests a
role for PR-11 in interfering with cell motility. Overexpression of
MEMO1 has been associated to aggressiveness and increased potential
for metastasis in pancreatic and mammary gland cell lines [42,43].
Lower levels of CAP1 (adenylyl cyclase-dependent protein 1) and
exportin-1 (XPO-1) were found at 10 h exposure. CAP1 is a structural
and highly conserved molecule involved in regulation of actin filaments
[44]. Knocking down expression of CAP1 through RNAi inhibited
proliferation and cell migration in three cancer cell models [45–47].
XPO-1 is tightly linked to cell-cycle regulation by mediating the nucleus
to cytoplasm transportation of proteins such as those encoded by
tumour suppressor genes [48]. In fact, overexpression of XPO-1 has
been associated to different cancer types such as leukemias, gliomas
and osteosarcomas [49–51]. Altogether, our findings potentially high-
light novel biological properties of PR-11 that could be of interest to
cancer research.
Our final approach aimed the identification of PR-11 interacting
proteins by means of affinity chromatography using the immobilized
peptide. After stringent washing steps, PR-11 bound proteins wereselectively eluted using soluble PR-11. One out of nine protein bands
appeared significantly enriched in a 1-D gel separation as revealed by sil-
ver staining. This particular protein (band 7) was identified as gC1qR
(complement component 1, q subcomponent binding protein), an acid
glycoprotein able to bind with high affinity to the globular portion of
complement C1q [52]. This protein is reported to be found in distinct
cell compartments such as mitochondria, nucleus and membranes of
various cell types [53–55] and its function has been related to growth
and survival of many tumour models [56]. More recently, Agemy et al.
(2013) identified gC1qR as a ligand and transporter of the positively
charged peptide CGKRK, which shares structural similarity to the N-
terminal portion of PR-11, coupled to a pro-apoptotic drug in breast can-
cer models. Once bound to surface gC1qR, the complex is internalized to
the mitochondria where the drug is released [57]. In agreement to our
findings, it has previously been reported that PR-39 is easily taken up
by fibroblasts, possibly by a receptor ligand exposed on the cell mem-
brane [21]. Given the noticeable enrichment of gC1qR as a target of PR-
11 in our affinity approach, here we provide preliminary evidence of
gC1qR mediating the interaction and internalization of this peptide.
The remaining eight putative PR-11 ligands, all found at vanishingly
small amounts, deserve further investigation to discriminate genuine
from unspecific interaction with PR-11. Anyhow, the identification of
two urea cycle components (ornithine carbamoyltransferase and
arginase-1) might indicate that those enzymes are capable to interact
with peptides rich in proline and arginine residues. This possible
interaction remains to be conclusively demonstrated. In corroboration
with our findings, a recent report revealed E. coli proteins related to
the metabolism of arginine and ornithine as ligands of PR-39 using a
microarray approach [58].
Various proteins known to reduce the cellular oxidative stress were
also co-eluted (e.g., catalase, peroxiredoxin-6 and glutathione S-
transferase isoforms). It was previously demonstrated that the PR-39
peptide decrease the production of superoxide radicals through binding
and inhibition of NADPH oxidase [13]. In this context, our findings
suggest a similar role for the PR-11 peptide broadening its anti-
inflammatory properties.
5. Conclusion
Here we aimed to provide the first inventory of proteomic alterations
caused by exposure of cultured fibroblasts to the PR-11 peptide. Proteins
1785G.S. Breguez et al. / Biochimica et Biophysica Acta 1864 (2016) 1775–1786that appeared significantly altered were dependent on the timing of
exposure and were predominantly related to signalling, transcription
and translation. Of note, our data revealed proteins involved with the
HIF-1α and NF-κB being altered, highlighting the capabilities of PR-11
to interfere with inflammatory processes and favour angiogenesis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbapap.2016.09.017.
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